Loading...
NPI 1184253650 · The Colony, TX · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Geneiq LLC is a clinical medical laboratory provider located in The Colony, Texas. This profile covers 6 Medicare and 19 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Geneiq LLC |
| Address | 3716 Standridge Dr Ste 204 |
| City | The Colony |
| State | TX |
| ZIP | 75056 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | April 6, 2020 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $401.7K |
| Medicare | $45.5K |
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
6 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 81226 | The lab analyst performs the technical lab test to detect the presence of common changes in the gene for cytochrome P450, family 2, subfamily D, polypeptide 6, also known as CYP2D6. | 60 | $440 | $24.3K |
| 81225 | The lab analyst performs the technical lab test to detect the presence of common changes in the gene for cytochrome P450, family 2, subfamily C, polypeptide 19, also known as CYP2C19. | 40 | $290 | $11.2K |
| 81227 | The lab analyst performs the technical lab test to detect the presence of common changes in the gene for cytochrome P450, family 2, subfamily C, polypeptide 9, also known as CYP2C9. | 20 | $170 | $3.4K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 40 | $70 | $3K |
| 81328 | The lab analyst performs the technical lab test to detect the presence of specific changes in the solute carrier organic anion transporter family, member 1B1 (SLCO1B) gene for common variants, such… | 20 | $170 | $2.6K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 40 | $30 | $1K |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 6 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
19 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 11,230 | $20 | $224.6K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 6,320 | $10 | $50.5K |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 330 | $90 | $28.2K |
| 81226 | The lab analyst performs the technical lab test to detect the presence of common changes in the gene for cytochrome P450, family 2, subfamily D, polypeptide 6, also known as CYP2D6. | 430 | $60 | $23.6K |
| 81225 | The lab analyst performs the technical lab test to detect the presence of common changes in the gene for cytochrome P450, family 2, subfamily C, polypeptide 19, also known as CYP2C19. | 410 | $40 | $16.7K |
| 81306 | The lab analyst performs the technical lab test to detect the presence of specific changes in the nudix hydrolase 15 gene (NUDT15). The test specifically targets common genetic variants such as *2,… | 250 | $40 | $11K |
| 81227 | The lab analyst performs the technical lab test to detect the presence of common changes in the gene for cytochrome P450, family 2, subfamily C, polypeptide 9, also known as CYP2C9. | 380 | $30 | $9.4K |
| 81231 | The lab analyst performs the technical lab test to analyze the common variants of the cytochrome P450 family 3 subfamily A member 5 gene (CYP3A5), such as *2, *3, *4, *5, *6, *7. | 350 | $20 | $8.3K |
| 81232 | The lab analyst performs the technical lab test to analyze the common variants of the dihydropyrimidine dehydrogenase (DPYD) gene, such as *2A, *4, *5, *6. | 260 | $30 | $7.3K |
| 81328 | The lab analyst performs the technical lab test to detect the presence of specific changes in the solute carrier organic anion transporter family, member 1B1 (SLCO1B) gene for common variants, such… | 260 | $30 | $7K |
Showing 1–10 of 19
How this provider's Medicaid billing volume and revenue compare to other Texas providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Texas median
19 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 30 | 340 | 400 | $50 | $553.5K |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 63 | 120 | 340 | $120 | $422K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 43 | 260 | 640 | $20 | $137.2K |
| 87502 | The lab analyst performs a test to determine the presence of multiple types or subtypes of influenza virus through nucleic acid detection using multiplex amplified probe technique and possibly… | 326 | 350 | 230 | $70 | $120.3K |
| 87634 | The lab analyst performs a test for respiratory syncytial virus (RSV) antigen detection using amplified nucleic acid probe technique. | 142 | 150 | 190 | $40 | $34.9K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 120 | 340 | 220 | $10 | $24.1K |
| 0002A | N/A | 84 | 350 | 70 | $20 | $7.4K |
| 0001A | N/A | 79 | 390 | 80 | $20 | $6.8K |
| 81226 | The lab analyst performs the technical lab test to detect the presence of common changes in the gene for cytochrome P450, family 2, subfamily D, polypeptide 6, also known as CYP2D6. | 5 | 30 | 50 | $20 | $3.8K |
| 81241 | The lab analyst performs the technical lab test to detect the presence of a common change, called the Leiden variant, in the gene for coagulation factor V, also known as Factor V Leiden or F5. | 16 | 30 | 80 | $10 | $3.5K |
Showing 1–10 of 19
Other providers in the same ZIP code as Geneiq LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Orthofix Us LLC | TX | Durable Medical Equipment & Medical Supplies | $0 | $76.2M |
| Care One Personal Health Services. Inc. | TX | Personal Care Attendant | $0 | $11.2M |
| Stanislav Tolkachjov | TX | Dermatology Physician | $1M | $1.1K |
| Tanner Mattison | TX | Anatomic Pathology & Clinical Pathology Physician | $27K | $271.7K |
| Rachel Corley | TX | Clinical Social Worker | $86.5K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.